Explore more publications!

Wellness Wire Moldova: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Wire Moldova.

Press releases published on February 11, 2026

Medical Device Contract Manufacturing Set to Reach $155.2 Billion Globally by 2030
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
CS Group (OTCQB: CSDX) Appoints Shah Teelani & Associates, a Dubai-Based PCAOB Auditor, to Consolidate All 2025 Financial Statements for CSDX, CS Interpharm GT LLC and CS Diagnostics Pharma GmbH
Dewpoint Therapeutics Selects First-in-Class MYC Condensate Modulator Development Candidate
DIL Walk Foundation Takes National and Global Leadership Role in Advancing Precision Health and Healthspan
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
Global Pharmaceutical Mass Spectrometry Market Poised to Reach $2.75 Billion by 2031 | MarketsandMarkets™
Psyence BioMed Announces Settlement of Shareholder Litigation
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
VIVUS Advances Patient Access with New Copay Assistance Program for PANCREAZE®
CalMHSA Selects Eleos as Statewide AI Technology Partner for Behavioral Health
Counslr Meets School Mental Health Demands with Further National Expansion and Strategic Partnerships
HealthEdge® Achieves HITRUST Risk-based, 2-year Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements
Wesley Pharmaceuticals Launches NAD+, Introducing a Signature Longevity and Skin Health Formulation to Its Product Lineup
Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
Senti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions